




1. (Currently amended) A compound represented by the formula (I):



 or 

1) a hydrogen atom,

2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R³ or R⁷ in combination with a carbon atom to which R³ or R⁷ is bonded, and an oxo group formed by R²¹ and R^{21'} together in combination with the carbon atom to which R²¹ and R^{21'} are bonded,

3) a C₁ to C₂₂ alkoxy group which may have a substituent,

4) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

5) a C₇ to C₂₂ aralkyloxy group which may have a substituent,

6) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

7) $RC(=Y)-O-$, wherein Y represents an oxygen atom or sulfur atom, and R represents

- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,
- c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
- d) a C_6 to C_{14} aryl group which may have a substituent,
- e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- f) a C_7 to C_{22} aralkyl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- h) a C_1 to C_{22} alkoxy group which may have a substituent,
- i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- j) a C_6 to C_{14} aryloxy group which may have a substituent,
- k) a C_3 to C_{14} cycloalkyl group which may have a substituent,
- l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
- m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

8) $R^{S1}R^{S2}R^{S3}SiO-$, wherein R^{S1} , R^{S2} and R^{S3} , the same or different, independently represent

- a) a C_1 to C_6 alkyl group or
- b) a C_6 to C_{14} aryl group,

9) a halogen atom,

10) $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

- a) a single bond,
- b) -CO-O-,
- c) -SO₂-O-,
- d) -CS-O- or
- e) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group

which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom,

R^{N1} and R^{N2}, the same or different, independently represent

- a) a hydrogen atom,
- b) a C₁ to C₂₂ alkyl group which may have a substituent,
- c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
- d) an aliphatic C₂ to C₂₂ acyl group which may have a substituent,
- e) an aromatic C₇ to C₁₅ acyl group which may have a substituent,
- f) a C₆ to C₁₄ aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C₇ to C₂₂ aralkyl group which may have a substituent,
- i) a C₁ to C₂₂ alkylsulfonyl group which may have a substituent,
- j) a C₆ to C₁₄ arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by

R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) R^{N4}SO₂-O-, wherein R^{N4} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) a C₆ to C₁₄ aryl group which may have a substituent,

c) a C₁ to C₂₂ alkoxy group which may have a substituent,

d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

e) a C₆ to C₁₄ aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

12) (R^{N5}O)₂PO-O-, wherein R^{N5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,


e) a C₇ to C₂₂ aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

13) $(R^{N1}R^{N2}N)_2PO-O-$, wherein R^{N1} and R^{N2} are the same as defined above or

14) $(R^{N1}R^{N2}N)(R^{N5}O)PO-O-$, wherein R^{N1} , R^{N2} and R^{N5} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

2. (Currently amended) The compound according to claim 1 represented by the formula (I-a):



wherein W is the same as defined above, and R^{3a} , R^{7a} , R^{16a} , R^{17a} , R^{20a} , R^{21a} and $R^{21a'}$, the same or different, independently represent

- 1) a hydrogen atom,
- 2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3a} or R^{7a} in combination with the carbon atom to which R^{3a} or R^{7a} is bonded, and an oxo group formed by R^{21a} and $R^{21a'}$ together in combination with a carbon atom to which R^{21a} and $R^{21a'}$ are bonded,
- 3) a C_1 to C_{22} alkoxy group which may have a substituent,
- 4) $R^aC(=Y^a)-O-$, wherein Y^a represents an oxygen atom or sulfur atom, and R^a represents

- a) a hydrogen atom,
 - b) a C₁ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) a C₆ to C₁₄ aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C₁ to C₂₂ alkoxy group which may have a substituent,
 - i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
 - j) a C₆ to C₁₄ aryloxy group which may have a substituent,
 - k) a C₃ to C₁₄ cycloalkyl group which may have a substituent,
 - l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
 - m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,
- 5) R^{aS1}R^{aS2}R^{aS3}SiO-, wherein R^{aS1}, R^{aS2} and R^{aS3}, the same or different, independently represent
- a) a C₁ to C₆ alkyl group or
 - b) a C₆ to C₁₄ aryl group or
- 6) R^{aN1}R^{aN2}N-R^{aM}-, wherein R^{aM} represents
- a) -CO-O- or
 - b) -CS-O-, provided that, in the leftmost bond a) or b) is bonded to the nitrogen

atom, and


R^{aN1} and R^{aN2} , the same or different, independently represent

- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,
- c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
- d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,
- e) an aromatic C_7 to C_{15} acyl group which may have a substituent,
- f) a C_6 to C_{14} aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C_7 to C_{22} aralkyl group which may have a substituent,
- i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,
- j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by

R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

- l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- m) a C_3 to C_{14} cycloalkyl group which may have a substituent or
- n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

3. (Currently amended) The compound according to claim 1 represented by the formula (I-b):



wherein W is the same as defined above, and R^{3b} , R^{7b} , R^{16b} , R^{17b} , R^{20b} , R^{21b} and $R^{21b'}$, the same or different, independently represent

- 1) a hydrogen atom,
- 2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3b} or R^{7b} in combination with the carbon atom to which R^{3b} or R^{7b} is bonded, and an oxo group formed by R^{21b} and $R^{21b'}$ together in combination with the carbon atom to which R^{21b} and $R^{21b'}$ are bonded,
- 3) a C_1 to C_{22} alkoxy group which may have a substituent,
- 4) $R^bC(=O)-O-$, wherein R^b represents
 - a) a C_1 to C_{22} alkyl group which may have a substituent,
 - b) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - c) a C_7 to C_{22} aralkyl group which may have a substituent,
 - d) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - e) a C_6 to C_{14} aryloxy group which may have a substituent,
 - f) a C_3 to C_{14} cycloalkyl group which may have a substituent or

g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

5) $R^{bS1}R^{bS2}R^{bS3}SiO-$, wherein R^{bS1} , R^{bS2} and R^{bS3} , the same or different, independently represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group or

6) $R^{bN1}R^{bN2}N-R^{bM}-$, wherein R^{bM} represents

a) $-CO-O-$ or

b) $-CS-O-$, provided that, the leftmost bond in a) or b) is bonded to the nitrogen

atom, and

R^{bN1} and R^{bN2} , the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,


c) a 3-membered to 14-membered non-aromatic heterocyclic group formed by

R^{bN1} and R^{bN2} together in combination with the nitrogen atom to which R^{bN1} and R^{bN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

d) a C_3 to C_{14} cycloalkyl group which may have a substituent or

e) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

4. (Currently amended) The compound according to claim 1 represented by the formula (I-c):



wherein W is the same as defined above, and R^{3c} , R^{7c} , R^{16c} , R^{17c} , R^{20c} , R^{21c} and $R^{21c'}$, the same or different, independently represent

- 1) a hydrogen atom,
- 2) a hydroxyl group or oxo group, provided that the oxo group is limited to an oxo group formed by R^{3c} or R^{7c} in combination with the carbon atom to which R^{3c} or R^{7c} is bonded, and an oxo group formed by R^{21c} and $R^{21c'}$ together in combination with the carbon atom to which R^{21c} and $R^{21c'}$ are bonded,
- 3) $R^cC(=O)-O-$, wherein R^c represents a C_1 to C_{22} alkyl group which may have a substituent,
- 4) $R^{cS1}R^{cS2}R^{cS3}SiO-$, wherein R^{cS1} , R^{cS2} and R^{cS3} , the same or different, independently represent
 - a) a C_1 to C_6 alkyl group or
 - b) a C_6 to C_{14} aryl group or
- 5) $R^{cN1}R^{cN2}N-R^{cM}-$, wherein R^{cM} represents $-CO-O-$, provided that the leftmost bond is bonded to the nitrogen atom, and

R^{cN1} and R^{cN2} , the same or different, independently represent


- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,

c) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{cN1} and R^{cN2} together in combination with the nitrogen atom to which R^{cN1} and R^{cN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

d) a C_3 to C_{14} cycloalkyl group which may have a substituent or

e) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

5. (Currently Amended) The compound according to claim 1 represented by the formula (I-d):



wherein R^{3d} and R^{16d} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) $R^dC(=O)-O-$, wherein R^d represents

a) a hydrogen atom,

- b) a C₁ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) a C₆ to C₁₄ aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C₁ to C₂₂ alkoxy group which may have a substituent,
 - i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
 - j) a C₆ to C₁₄ aryloxy group which may have a substituent or
 - k) a 5-membered to 14-membered heteroaryloxy group which may have a substituent or
- 6) R^{dN1}R^{dN2}N-CO-O-, wherein R^{dN1} and R^{dN2}, the same or different, independently represent
- a) a hydrogen atom,
 - b) a C₁ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) a C₆ to C₁₄ aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C₃ to C₁₄ cycloalkyl group which may have a substituent,

i) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{dN1} and R^{dN2} together in combination with the nitrogen atom to which R^{dN1} and R^{dN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{7d} and R^{21d} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) $R^dC(=O)-O-$, wherein R^d is the same as defined above,
- 6) $R^{dN1}R^{dN2}N-CO-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,
- 7) $R^{dN1}R^{dN2}N-SO_2-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,
- 8) $R^{dN1}R^{dN2}N-CS-O-$, wherein R^{dN1} and R^{dN2} are the same as defined above,
- 9) $R^{dN4}-SO_2-O-$, wherein R^{dN4} represents

- a) a C_1 to C_{22} alkyl group which may have a substituent,
- b) a C_6 to C_{14} aryl group which may have a substituent,
- c) a C_1 to C_{22} alkoxy group which may have a substituent,
- d) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- e) a C_6 to C_{14} aryloxy group which may have a substituent,
- f) a 5-membered to 14-membered heteroaryloxy group which may have a

substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a

substituent,

10) (R^{dN5}O)₂PO-O-, wherein R^{dN5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C₇ to C₂₂ aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

11) (R^{dN1}R^{dN2}N)₂PO-O-, wherein R^{dN1} and R^{dN2} are the same as defined above or

12) (R^{dN1}R^{dN2}N)(R^{dN5}O)PO-O-, wherein R^{dN1}, R^{dN2} and R^{dN5} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

6. (Currently amended) The compound according to claim 1, wherein R⁷ and/or R²¹ are independently represented by RC(=Y)-O-, wherein Y and R are the same as defined above or R^{N1}R^{N2}N-R^{M'}-, wherein R^{M'} represents


a) -CO-O- or

b) -CS-O-, provided that, the leftmost bond in a) or b) is bonded to the nitrogen

atom, and

R^{N1} and R^{N2} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

7. (Currently Amended) The compound according to claim 5 represented by the formula (I-e):



wherein R^{3e} , R^{16e} and R^{21e} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) an aliphatic C_2 to C_6 acyl group which may have a substituent or
- 6) $R^{eN1}R^{eN2}N-CO-O-$, wherein R^{eN1} and R^{eN2} independently represent

a) a hydrogen atom or


b) a C_1 to C_6 alkyl group which may have a substituent, and

R^{7e} represents $R^e-C(=Y^e)-O-$, wherein Y^e represents an oxygen atom or sulfur atom, and R^e represents

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

- c) a C₆ to C₁₄ aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C₇ to C₁₀ aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent
- h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_e represents

- i) -CHR^{eN4}-,
- ii) -NR^{eN5}-,
- iii) -O-,
- iv) -S-,
- v) -SO- or
- vi) -SO₂-,

R^{eN1} represents

- i) a hydrogen atom or

ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN2} represents

i) a hydrogen atom or

ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN3} and R^{eN4}, the same or different, independently represent

i) a hydrogen atom,

ii) a C₁ to C₆ alkyl group which may have a substituent,

iii) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

iv) a C₆ to C₁₄ aryl group which may have a substituent,

v) a 5-membered to 14-membered heteroaryl group which may have a substituent,

vi) a C₇ to C₁₀ aralkyl group which may have a substituent,

vii) a C₃ to C₈ cycloalkyl group which may have a substituent,

viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

xi) -NR^{eN6}R^{eN7}, wherein R^{eN6} and R^{eN7}, the same or different, independently represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or

xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN4} together in combination with the carbon atom to which R^{eN3} and R^{eN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a

substituent, and

R^{eN5} represents

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- iv) a C_6 to C_{14} aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C_7 to C_{10} aralkyl group which may have a substituent,
- vii) a C_3 to C_8 cycloalkyl group which may have a substituent,
- viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN5} together in combination with the nitrogen atom to which R^{eN3} and R^{eN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_e , n , R^{eN3} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN2} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN1} and R^{eN2} together, wherein the 5-membered to 14-membered

non-aromatic heterocyclic group may have a substituent,


C)

X_e , n , R^{eN2} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN3} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN1} and R^{eN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_e , n , R^{eN1} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN2} and R^{eN3} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN2} and R^{eN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{eN8} and R^{eN9} , the same or different, independently represent

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) a C_6 to C_{14} aryl group which may have a substituent,

iv) a 5-membered to 14-membered heteroaryl group which may have a

substituent,

v) a C₇ to C₁₀ aralkyl group which may have a substituent or

vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

8. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} are independently represented by R^{e1}C(=Y^{e1})-O-, wherein Y^{e1} represents an oxygen atom or sulfur atom, and R^{e1} represents

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,


3) a C₆ to C₁₀ aryl group which may have a substituent,

4) a 5-membered to 14-membered heteroaryl group which may have a substituent,

5) a C₇ to C₁₀ aralkyl group which may have a substituent or

6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

9. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} are independently represented by R^{e2}C(=Y^{e2})-O-, wherein Y^{e2} represents an oxygen atom or sulfur atom, and R^{e2} represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,

X_1 represents

- 1) $-\text{CHR}^{\text{eN13}}-$,
- 2) $-\text{NR}^{\text{eN14}}-$,
- 3) $-\text{O}-$,
- 4) $-\text{S}-$,
- 5) $-\text{SO}-$ or
- 6) $-\text{SO}_2-$,

R^{eN10} and R^{eN11} , the same or different, independently represent

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

R^{eN12} and R^{eN13} , the same or different, independently represent

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) $-NR^{eN15}R^{eN16}$, wherein R^{eN15} and R^{eN16} , the same or different, independently represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent, or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN12} and R^{eN13} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{eN14} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) a 5-membered to 14-membered non-aromatic heterocyclic group formed together by the nitrogen atom to which R^{eN14} is bonded, and one substituent selected from the

group consisting of R^{eN10} , R^{eN11} and R^{eN12} , wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or


12) a 5-membered to 14-membered non-aromatic heterocyclic group formed together by the nitrogen atom to which R^{eN14} is bonded, and two substituents selected from the group consisting of R^{eN10} , R^{eN11} and R^{eN12} , wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

B)

n , X_1 , R^{eN11} , R^{eN13} and R^{eN14} are the same as defined above, and R^{eN10} and R^{eN12} together form a 5-membered to 14-membered non-aromatic heterocyclic group, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

10. (Currently amended) The compound according to claim 5, wherein X_1 represents $-NR^{eN14}-$, wherein NR^{eN14} is the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

11. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e3}C(=Y^{e3})-O-$, wherein Y^{e3} represents an oxygen atom or sulfur atom, and R^{e3} represents a group of the formula (V):



wherein n_1 represents an integer of 0 to 6,

R^{eN17} represents


- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{eN18} represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,
- 6) a morpholin-4-yl group which may have a substituent or
- 7) a piperazin-1-yl group which may have a substituent; a pharmacologically

acceptable salt thereof, or a hydrate thereof ~~of these~~.

12. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e4}CO-O-$, wherein R^{e4} represents a group of the formula (VI):



wherein n_2 and n_3 , the same or different, independently represent an integer of 0 to 4,

X₂ represents

- 1) -CHR^{eN21}-,
- 2) -NR^{eN22}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO₂-,

R^{eN19} represents

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN20} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₄ aryl group which may have a substituent or
- 4) a C₇ to C₁₀ aralkyl group which may have a substituent,

R^{eN21} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,

7) a C₃ to C₈ cycloalkyl group which may have a substituent,
8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) -NR^{eN23}R^{eN24}, wherein R^{eN23} and R^{eN24}, the same or different, independently represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or


11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{eN22} represents

1) a hydrogen atom,
2) a C₁ to C₆ alkyl group which may have a substituent,
3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
4) a C₆ to C₁₄ aryl group which may have a substituent,
5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
6) a C₇ to C₁₀ aralkyl group which may have a substituent,
7) a C₃ to C₈ cycloalkyl group which may have a substituent,
8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

13. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e5}CO-O-$, wherein R^{e5} represents a group of the formula (VII):



wherein n_4 represents 1 or 2,

R^{eN25} represents


- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{eN26} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent; a pharmacologically

acceptable salt thereof, or a hydrate thereof ~~of these~~.

14. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e6}CO-O-$, wherein R^{e6} represents a group of the formula (VIII):



wherein n_2 and n_3 , the same or different, independently represent an integer of 0 to 4,

X₃ represents

- 1) -CHR^{eN29}-,
- 2) -NR^{eN30}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO₂-,

R^{eN27} represents

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN28} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₄ aryl group which may have a substituent or
- 4) a C₇ to C₁₀ aralkyl group which may have a substituent,

R^{eN29} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₁ to C₆ alkoxy group which may have a substituent,
- 5) a C₆ to C₁₄ aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C₇ to C₁₀ aralkyl group which may have a substituent,
8) a C₃ to C₈ cycloalkyl group which may have a substituent,
9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) -NR^{eN31}R^{eN32}, wherein R^{eN31} and R^{eN32}, the same or different, independently represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent, or form a 5-membered to 14-membered non-aromatic heterocyclic group together with the nitrogen atom to which R^{eN31} and R^{eN32} are bonded or


12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{eN30} represents

1) a hydrogen atom,
2) a C₁ to C₆ alkyl group which may have a substituent,
3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
4) a C₆ to C₁₄ aryl group which may have a substituent,
5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
6) a C₇ to C₁₀ aralkyl group which may have a substituent,
7) a C₃ to C₈ cycloalkyl group which may have a substituent,
8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

15. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e7}CO-O-$, wherein R^{e7} represents a group of the formula (IX):




wherein n_5 represents an integer of 1 to 3, and

R^{eN33} represents

- 1) an amino group,
- 2) an amino group which may have a substituent,
- 3) a pyrrolidin-1-yl group which may have a substituent,
- 4) a piperidin-1-yl group which may have a substituent or
- 5) a morpholin-4-yl group which may have a substituent; a pharmacologically

acceptable salt thereof, or a hydrate thereof ~~of these~~.

16. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e8}CO-O-$, wherein R^{e8} represents a group of the formula (X):



wherein n_5 represents an integer of 1 to 3,

R^{eN34} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent, and

R^{eN35} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 4) a 3-membered to 8-membered non-aromatic heterocyclic group which may

have a substituent,


- 5) a C_6 to C_{14} aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C_7 to C_{10} aralkyl group which may have a substituent,
- 8) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent or

- 9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent; a

pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

17. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e9}CO-O-$, wherein R^{e9} represents a group of the formula (XI):




wherein n_5 represents an integer of 1 to 3, and

R^{eN36} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 4) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 5) a C_7 to C_{10} aralkyl group which may have a substituent,
- 6) a pyridyl group which may have a substituent or
- 7) a tetrahydropyranyl group which may have a substituent; a pharmacologically

acceptable salt thereof, or a hydrate thereof ~~of these~~.

18. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e10}CO-O-$, wherein R^{e10} represents a group of the formula (XII):



wherein m_1 , m_2 , m_3 , and m_4 , the same or different, independently represent 0 or 1,

n_5 represents an integer of 1 to 3, and


R^{eN37} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent or


10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

19. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e11}CO-O-$, wherein R^{e11} represents a group of the formula (XIII):




wherein m_5 represents an integer of 1 to 3, and n_5 represents 2 or 3; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

20. (Currently amended) The compound according to claim 5, wherein R^{7e} and/or R^{21e} independently represent $R^{e12}CO-O-$, wherein R^{e12} represents a group selected from a group consisting of:



group selected from a group consisting of




both of which may have a substituent on the ring; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

21. (Currently amended) The compound according to claim 1, wherein R^{16} is a hydroxyl group; a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.


22. (Currently amended) The compound according to claim 1, wherein

[1] W is




R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16} , R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[2] W is




R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16} , R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[3] W is



R^3 , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,


[4] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded,


R^3 , R^{16} and R^{20} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} is a hydrogen atom,

[5] W is




R^3 , R^{16} , R^{20} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and $R^{21'}$ are a hydrogen atom,

[6] W is




R^3 , R^7 , R^{16} and R^{21} are a hydroxyl group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[7] W is



R^3 , R^{17} , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{20} and $R^{21'}$ are a hydrogen atom or

[8] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3 and R^{16} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and R^{20} are a hydrogen atom; a

pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~.

23. (Original) The compound according to claim 1, which is (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylhomopiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-(piperidin-1-yl)piperidin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-7-((4-ethylpiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricoso-8,12,14-trien-11-olide, (8E,12E,14E)-7-(N-(3-(N',N'-dimethylamino)propyl)-N-methylcarbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricoso-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((piperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(N-methyl-N-(1-methylpiperidin-4-yl)carbamoyloxy)-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylhomopiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-(4-hydroxypiperidin-1-yl)piperidin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-((4-(morpholin-4-yl)piperidin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-7-((4-ethylhomopiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylpiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-7-(((1S,4S)-5-isopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide,

(8E,12E,14E)-7-(N-(2-(N',N'-dimethylamino)ethyl)-N-methylcarbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide,

(8E,12E,14E)-7-(N-(2-(N',N'-dimethylamino)ethyl)carbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide or

(8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide.

24. (Original) The compound according to claim 1, which is (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(N-methyl-N-(1-methylpiperidin-4-yl)carbamoyloxy)-18,19-epoxytricos-8,12,14-trien-11-olide,

(8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylhomopiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-7-((4-ethylhomopiperazin-1-yl)carbonyl)oxy-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-3,16,21-trihydroxy-7-((4-isopropylpiperazin-1-yl)carbonyl)oxy-6,10,12,16,20-pentamethyl-18,19-epoxytricos-8,12,14-

trien-11-olide or (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide.

25. (Currently amended) A ~~medicine~~ pharmaceutical composition comprising the compound according to claim 1 in a therapeutically effective amount, a pharmacologically acceptable salt thereof, or a hydrate thereof ~~of these~~ as an active ingredient.

26. – 29. (Canceled)

30. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as an angiogenesis inhibitor.

31. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as an antitumor agent.

32. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a therapeutic agent for treating hemangioma.

33. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a cancer metastasis inhibitor.

34. – 35. (canceled).

36. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a therapeutic agent for inflammatory diseases consisting of deformat arthritis, rheumatoid arthritis, psoriasis, and delayed hypersensitive reaction.

37. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a therapeutic agent for treating atherosclerosis.

38. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a therapeutic agent for treating a solid cancer.


39. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 38, wherein the solid tumor is lung cancer, brain tumor, breast cancer, prostate cancer, ovarian cancer, colon cancer or melanoma.

40. (Currently amended) The ~~medicine~~ pharmaceutical composition according to claim 25 as a therapeutic agent for treating leukemia.


41. – 50. (canceled)

51. (Original) A method for producing a 6-deoxy 11107 compound, characterized in that the

method comprises culturing a microorganism belonging to the genus *Streptomyces*, which is capable of producing a compound of the formula (I):



wherein [1] W is



R³ and R²¹ are a hydroxyl group, R⁷ is an acetoxy group, and R¹⁶, R¹⁷, R²⁰ and R^{21'} are a hydrogen atom or


[2] W is




R³ and R²¹ are a hydroxyl group, R⁷ is an acetoxy group, and R¹⁶, R¹⁷, R²⁰ and R^{21'} are a hydrogen atom; and collecting the compound as defined in [1] or [2] (hereinafter referred to as “6-deoxy 11107 compound”) from the culture.

52. (Original) *Streptomyces* sp. strain A-1543 (FERM BP-8442) that is capable of producing the 6-deoxy 11107 compound according to claim 51.

53. (Original) A method for producing a 6-deoxy compound by biologically converting a compound of the formula (I):




wherein [1] W is




R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16} , R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom (hereinafter referred to as “6-deoxy 11107B”) into a compound of the formula (I), wherein

[3] W is




R^3 , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[4] W is




R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3 , R^{16} and R^{20} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} is a hydrogen atom,

[5] W is



R^3 , R^{16} , R^{20} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and $R^{21'}$ are a hydrogen atom,

[6] W is




R^3 , R^7 , R^{16} and R^{21} are a hydroxyl group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[7] W is



R^3 , R^{17} , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{20} and $R^{21'}$ are a hydrogen atom or

[8] W is



R^{21} and $R^{21'}$ form an oxo group together with the carbon atom to which R^{21} and $R^{21'}$ are bonded, R^3 and R^{16} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and R^{20} are a hydrogen atom (these compounds are hereinafter referred to as “6-deoxy compounds”), comprising

- 1) a step that can conduct the biological conversion, the step of incubating 6-deoxy 11107B in the presence of a culture solution of a strain selected from microorganisms belonging to bacteria or a product prepared from culture cells of the strain, and
- 2) collecting a 6-deoxy compound from the incubated solution.

54. (Original) The method according to claim 53, wherein the microorganism belonging to bacteria is strain A-1544 (FERM BP-8446) or strain A-1545 (FERM BP-8447).

55. (Original) Strain A-1544 (FERM BP-8446) or strain A-1545 (FERM BP-8447) which is capable of converting 6-deoxy 11107B into a 6-deoxy compound.